Bangladesh vs Ghana: Average cost of multi drug-resistant tuberculosis treatment
Bangladesh
466 constant 2022 US$
in 2024
Ghana
500 constant 2022 US$
in 2024
Bangladesh rank
81st
Ghana rank
78th
Average cost of multi drug-resistant tuberculosis treatment over time
- Bangladesh
- Ghana
How they compare
Ghana currently reports 500 constant 2022 US$ against 466 constant 2022 US$ in Bangladesh, a difference of 34 constant 2022 US$.
That makes Ghana's figure about 1.1 times Bangladesh's.
The two have swapped places 3 times across 8 shared years of data; in 2017 it was Bangladesh ahead.
Bangladesh ranks 81st and Ghana ranks 78th of 92 countries.
Ghana has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Bangladesh | Ghana | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,374 constant 2022 US$ | 1,860 constant 2022 US$ | 485.67 constant 2022 US$ | Ghana |
| 2020s | 769 constant 2022 US$ | 1,116 constant 2022 US$ | 346.8 constant 2022 US$ | Ghana |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Bangladesh or Ghana?
- Ghana, at 500 constant 2022 US$ against 466 constant 2022 US$ in Bangladesh as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Bangladesh and Ghana?
- 34 constant 2022 US$, with Ghana ahead.
- How many years of comparable data are there for Bangladesh and Ghana?
- 8 years are reported by both, from 2017 to 2024.
- How do Bangladesh and Ghana rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Bangladesh ranks 81st and Ghana ranks 78th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.